Boston Biomedical announces the Grand Opening of its Cambridge Headquarters

 Boston Biomedical announces the Grand Opening of its Cambridge Headquarters

PR Newswire

CAMBRIDGE, Mass., July 12, 2013

CAMBRIDGE, Mass., July 12, 2013 /PRNewswire/ --Boston Biomedical, Inc.this
weekcelebrated the relocation of its headquarters to Cambridge, Massachusetts
with a grand opening ceremony. Academic, business and government leaders, as
well as executives from Dainippon Sumitomo Pharma Co., Ltd. (DSP), the parent
company of BBI, joined the celebration.

"We are pleased to celebrate the opening of our new facility, which will
greatly expand the efforts of the Boston Biomedical team in our quest for
better therapies for cancer," said Dr. Chiang J. Li, M.D. FACP, the founder,
president, and CEO of Boston Biomedical, Inc. "With this facility, and the
support of DSP, we intend to make significant progress in translating exciting
discoveries in cancer stem cell science into innovative therapeutics for
cancer patients."

Boston Biomedical is focusing on developing the next generation of targeted
cancer therapeutics, and is recognized as an industry leader in the creation
of drugs designed to target cancer stem cells (CSC) which are highly malignant
and considered to be fundamentally responsible for cancer growth, recurrence,
drug-resistance and metastasis.

"Investing in education, innovation and infrastructure is a winning growth
strategy for Massachusetts and is the reason we lead the world in life
sciences," said Governor Deval Patrick. "We welcome Boston Biomedical's new
facility in Cambridge and thank them for their commitment to growing and
creating jobs here."

"We chose Cambridge as the location for Boston Biomedical's new headquarters
to capitalize on the easy access to leading-edge scientific research and
technology developed by the surrounding world-class universities and research
institutes," said Mr. Masayo Tada, President and CEO of DSP, and Chairman of
Boston Biomedical, Inc. The new, 64,000-square-foot facility is located at 640
Memorial Drive, a historical landmark situated at the epicenter of the
region's life science and technology clusters.

"Despite the great advances in the field of oncology over the past few
decades, cancer is the second-most common cause of death in the nation," said
Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life
Sciences Center, the quasi-public agency tasked with implementing the state's
10-year, $1-billion Life Sciences Initiative. "We look forward to Boston
Biomedical's continued R&D efforts here in Massachusetts, as they make
advances that may hold promise for cancer patients across the world.We also
welcome the increased presence of DSP in the Massachusetts life sciences
community, part of a growing relationship between the life sciences clusters
in Massachusetts and Japan."

With a new state-of-the-art facility and support from DSP, Boston Biomedical
aims to continue to leverage its scientific excellence and leadership in order
to advance the development of novel cancer therapeutics.

About Boston Biomedical, Inc.
Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D.
FACP) was founded in November, 2006 and is fully owned by Dainippon Sumitomo
Pharma Co., Ltd. Boston Biomedical is focused on the research and development
of novel cancer therapeutics, and has developed a world-leading product
pipeline targeting cancer stem cells. Boston Biomedical's innovation in drug
discovery has received a number of recognitions and awards in the United
States, including sole recipient of the Frost & Sullivan 2010 North American
Drug Discovery Technology Innovation of the Year Award, 2011 Biotech Pioneer
Award (Alexandria Oncology Summit). Boston Biomedical is headquartered in
Cambridge, Massachusetts, USA. Additional information about the company and
its product pipeline can be found at bostonbiomedical.com.

About Dainippon Sumitomo Pharma Co., Ltd. (DSP)
Dainippon Sumitomo Pharma Co., Ltd. (DSP) is a multi-billion dollar, top-ten
listed, pharmaceutical company in Japan with a diverse portfolio of
pharmaceutical products. DSP aims to produce innovative pharmaceutical
products in the Psychiatry & Neurology field and Oncology field, which are
designated as focus therapeutic areas. The DSP Group is enhancing its presence
in oncology with the aim of making it a future core business area next to CNS.
DSP has more than 7,000 employees worldwide. Additional information about DSP
is available through its corporate website at http://www.ds-pharma.com/.

About DSP Global Oncology R&D
In September 2012 the DSP Cancer Institute was established in Japan as an
organization independent of the Research Division under direct control of the
President, Masayo Tada. In charge of the DSP Cancer Institute is Chiang J. Li
MD FACP, the Head of Global Oncology for DSP Group. DSP aims to continually
create leading-edge, breakthrough products under the strong collaboration
between BBI and the DSP Cancer Institute.

SOURCE Boston Biomedical, Inc.

Website: http://www.bostonbiomedical.com
Contact: Paula Magoon, pmagoon@bostonbiomedical.com, 617.674.8575